Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SCD Clear all
Completed Phase 4 Interventional

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

NCT03176849
View directory record Official record
Conditions
Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions
Vitamin D3, Standard Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

NCT06374238
View directory record Official record
Conditions
Pain, Sickle Cell Disease
Interventions
CBT+ Health coach, CBT w/o Health Coach ( self-guided), Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 30 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Mobile, Alabama • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875
View directory record Official record
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

NCT00005783
View directory record Official record
Conditions
Hemoglobin SC Disease, Sickle Cell Anemia
Interventions
Recombinant-methionyl human stem cell factor
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:01 AM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational

Retrospective Real World Oxbryta® Data Collection and Analysis Study

NCT04930328
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oxbryta® (voxelotor) 500-mg Tablets
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Farmington, Connecticut • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Not applicable Interventional

A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)

NCT02026102
View directory record Official record
Conditions
Systolic Heart Failure, Sudden Cardiac Death
Interventions
ICD Decision Aid Toolkit
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

NCT00142051
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
nitric oxide, oxygen
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

NCT04684381
View directory record Official record
Conditions
Sickle Cell Disease, Pharmacokinetics
Interventions
L-glutamine
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational

sPLA2 in EBC During Acute Chest Syndrome

NCT03250585
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Exhaled Breath Condensate (EBC), Plasma Sample
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Results available

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

NCT03226691
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional

Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America

NCT06229418
View directory record Official record
Conditions
Cardiac Arrest, Sudden Cardiac Arrest
Interventions
DFR AED Pilot Program
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Clemmons, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational Results available

S-ICD® System Post Approval Study

NCT01736618
View directory record Official record
Conditions
Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest
Interventions
S-ICD System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
87
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Suspended Not applicable Interventional

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)

NCT05457790
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Interventions
ACT Intervention, Waitlist
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease

NCT02857023
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Cogmed RM
Behavioral
Lead sponsor
Steven J. Hardy
Other
Eligibility
7 Years to 16 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Phase 3 Interventional

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 65 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional Results available

Sickle Cell Disease (SCD) Bone Pain Study

NCT05283148
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Low Bone Density, Osteoporosis, Osteopenia, Vertebral Fracture, Vertebral Compression, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
Interventions
Dual-energy X-ray absorptiometry, Vertebral fracture analysis, Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

NCT03492099
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting No phase listed Observational

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

NCT05170412
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Results available

A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

NCT04869787
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704
View directory record Official record
Conditions
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

NCT01316549
View directory record Official record
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
Interventions
Fludarabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Jul 22, 2026, 5:01 AM EDT